The Paris System for reporting urinary cytology improves the negative predictive value of high-grade urothelial carcinoma
Tóm tắt
The Paris System (TPS) for reporting urinary cytology differs from conventional systems (CS) in that it focuses on the diagnosis of high-grade urothelial carcinoma (HGUC). This study investigated the impact of TPS implementation on the diagnostic accuracy of HGUC by comparing it with our institutional CS. A total of 649 patients who underwent transurethral resection of bladder tumor (TURBT) between January 2009 and December 2020 were included in this study. Our institution adopted TPS to report urinary cytology in February 2020. The diagnostic accuracy of HGUC in preoperative urinary cytology was compared with the presence or absence of HGUC in resected specimens of TURBT before and after TPS implementation. After implementing TPS in urinary cytology, 89 patients were reviewed and compared with 560 patients whose urinary cytology was diagnosed by CS. TPS and CS for detecting HGUC had 56.0% and 58.2% sensitivity, 97.8% and 91.2% specificity, and 93.3% and 87.9% positive predictive values, respectively. There were no significant differences between TPS and CS in terms of sensitivity, specificity, and positive predictive value for HGUC (P = 0.83, 0.21, 1.00). On the other hand, the negative predictive value for HGUC using TPS was 80.0%, which was significantly higher than that of CS (66.4%, P = 0.04) The multivariate logistic regression analysis indicated that not using TPS was one of the independent predictive factors associated with false-negative results for HGUC (odds ratio, 2.26; 95% confidence interval, 1.08–4.77; P = 0.03). In instances where urinary cytology is reported as negative for HGUC by TPS, there is a low probability of HGUC, indicating that TPS has a potential diagnostic benefit.
Tài liệu tham khảo
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.
Abraham J, Gulley JL. The Bethesda handbook of clinical oncology. 5th ed. Philadelphia: Wolters Kluwer Health; 2019.
Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (ta, T1, and carcinoma in situ). Eur Urol. 2022;81:75–94.
Eble JN, Sauter G, Epstein JI. World Health Organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC Press; 2004.
Miyamoto H, Miller JS, Fajardo DA, Lee TK, Netto GJ, Epstein JI. Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system. Pathol Int WHO. 2010;60:1–8.
Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, et al. Bladder cancer. Lancet. 2016;388:2796–810.
Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15:25–41.
Brown FM. Urine cytology. It is still the gold standard for screening? Urol Clin N Am. 2000;27:25–37.
Rosenthal DL, Wojcik EM, Kurtycz DFI. The Paris System for reporting urinary cytology. New York: Springer; 2016.
Cowan ML, Rosenthal DL, VandenBussche CJ. Improved risk stratification for patients with high-grade urothelial carcinoma following application of the Paris System for reporting urinary cytology. Cancer Cytopathol. 2017;125:427–34.
Meilleroux J, Daniel G, Aziza J, d’Aure DM, Quintyn-Ranty ML, Basset CM, et al. One year of experience using the Paris System for reporting urinary cytology. Cancer Cytopathol. 2018;126:430–6.
VandenBussche CJ. A review of the Paris system for reporting urinary cytology. Cytopathology. 2016;27:153–6.
Jung A, Nielsen ME, Crandell JL, Palmer MH, Bryant AL, Smith SK, et al. Quality of life in non-muscle-invasive bladder cancer survivors: a systematic review. Cancer Nurs. 2019;42:E21-33.
Sullivan NM, Sutter VL, Mims MM, Marsh VH, Finegold SM. Clinical aspects of bacteremia after manipulation of the genitourinary tract. J Infect Dis. 1973;127:49–55.
Rai S, Lali BS, Venkataramana CG, Philipose CS, Rao R, Prabhu GL. A quest for accuracy: evaluation of the Paris system in diagnosis of urothelial carcinomas. J Cytol. 2019;36:169–73.
Stanzione N, Ahmed T, Fung PC, Cai D, Lu DY, Sumida LC, et al. The continual impact of the Paris System on urine cytology, a 3-year experience. Cytopathology. 2020;31:35–40.
McIntire PJ, Kilic I, Pambuccian SE, Wojcik EM, Barkan GA. The Paris System for reporting urinary cytology reduces atypia rates and does not alter the negative predictive value of urine cytology. J Am Soc Cytopathol. 2021;10:14–9.
Lee PJ, Owens CL, Lithgow MY, Jiang Z, Fischer AH. Causes of false-negative for high-grade urothelial carcinoma in urine cytology. Diagn Cytopathol. 2016;44:994–9.
VandenBussche CJ, Rosenthal DL, Olson MT. Adequacy in voided urine cytology specimens: the role of volume and a repeat void upon predictive values for high-grade urothelial carcinoma. Cancer Cytopathol. 2016;124:174–80.
Olson MT, Boonyaarunnate T, Aragon Han P, Umbricht CB, Ali SZ, Zeiger MA. A tertiary center’s experience with second review of 3885 thyroid cytopathology specimens. J Clin Endocrinol Metab. 2013;98:1450–7.